Alessandro Riva

Intima Bioscience, Inc. is a bioscience company that is advancing checkpoint cell therapy for solid tumors with curative intent. The private company is based in New York, NY. The company combines the use of patients' own immune cells with immune checkpoint targeting. Intima is currently running a phase 1/2 clinical study of its checkpoint cell therapy, which targets the immune checkpoint cish in patients with gastrointestinal and colon cancers. Alessandro Riva has been the CEO of the company since 2021.

Ichnos Sciences, Inc. operates as a biotechnology company. It provides curative therapies that extend human life. The company was founded in 2019 and is headquartered in Paramus, NJ.

Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA.